Informations générales (source: ClinicalTrials.gov)
Effect of Prehabilitation in Gastroesophageal Adenocarcinoma: Study Protocol of a Multicentric, Randomised Control Trial (PREHAB)
Interventional
Phase 3
University Hospital, Clermont-Ferrand (Voir sur ClinicalTrials)
janvier 2017
mars 2018
29 juin 2024
Perioperative chemotherapy is the gold standard treatment in the resectable and advanced
gastroesophageal adenocarcinoma. The efficacy of this strategy has been demonstrated in
two randomized studies (1,2). It reduces tumour size before surgery, treats
micrometastases and evaluates chemosensitivity. Disease free and overall survival rates
were significantly improved with perioperative chemotherapy compared to surgery alone.
However, the limitation of these studies is that among all patients requiring
chemotherapy, almost 70% of patients will not have the complete sequence. This sequence
is defined by the administration of 2 to 4 cycles before and 2 to 4 cycles after the
surgery, according to the protocol. The major cause of absence or impossibility of
realization of postoperative chemotherapy was the presence of postoperative complication,
postoperative serious asthenia and impaired nutritional and physical status (1,2). Poor
physical condition assessed by cardiopulmonary exercise testing, reflecting a reduced
physiological reserve, is predictive of postoperative complications (3,4). A physical
training, even during a short period and on a various population, is beneficial in
improving physical condition, cardiopulmonary function and muscular mass of the patient
(5-8). A prehabilitation over a 6 week period between surgical consultation and surgery
decreases postoperative morbidity and the hospital stay in cardiovascular surgery but no
study has ever been performed in the gastric or oesophageal cancer (7,9).
Prehabilitation revolves around three axes: 1) a physical training based on initial
cardiopulmonary exercise testing (VO2peak, anaerobic threshold (AT) and 6-min walk test
(6MWT)), 3 times by week, supervised by a physical therapist 2) a nutritional care to
ensure the compliance of the nutrition program and adapt the nutritional management based
on protein and energy needs and on the level of spontaneous oral intake and 2) a
psychological treatment by a psychologist to reduce preoperative anxiety. To our
knowledge, no study ever focused on the gastroesophageal cancer. The benefit of
prehabilitation in this cancer may be particularly important because 1) this surgery is
associated with a high postoperative morbidity (40%, especially respiratory) and
mortality (5%) 2) the physical and nutritional status of these patients is often
precarious (cancer cachexia, gastroesophageal obstruction), and 3) the need to
preoperative chemotherapy declines physical reserves and is associated with a lengthening
of the time between consultation and surgery of more than 3 months (10). Also, the
investigators hypothesize that with a physical training, a personalized nutritional
support and a psychologist management may decrease postoperative complications, increase
postoperative nutritional status and so, would allow for more patients to receive their
full cancer treatment. The aim of this study was to evaluate, in gastroesophageal
adenocarcinoma, the effect of prehabilitation compared to conventional care, the
percentage of patients reaching the complete oncological treatment decided in a
multidisciplinary tumour board.
Etablissements
Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
---|---|---|---|---|---|
CHU Clermont-Ferrand - 63003 - Clermont-Ferrand - France | Patrick LACARIN | Contact (sur clinicalTrials) |
Critères
Tous
Inclusion Criteria:
> 18 years old.
- Patient who agreed to participate in the study
- Patient requiring surgical management for the cancer of the esophagus or stomach.
- Patient who have a standard perioperative chemotherapy:
For esophageal cancer: chemotherapy with 5-FU (or LV5-FU2) -platinum salts or Taxane-salt
platinum salts, 2 to 4 cycles pre- and postoperatively.
For stomach cancer: Perioperative chemotherapy with Epirubicin and cisplatin-5-FU (ECF),
Epirubicin-oxaliplatin-5FU (EOX) or 5-FU (or LV5FU) - platinum salts, 2 to 4 cycles.
- subscribe to the French national health insurance system and give their written
consent.
- Patient speak and understand French.
- effective contraception for patients of childbearing age
> 18 years old.
- Patient who agreed to participate in the study
- Patient requiring surgical management for the cancer of the esophagus or stomach.
- Patient who have a standard perioperative chemotherapy:
For esophageal cancer: chemotherapy with 5-FU (or LV5-FU2) -platinum salts or Taxane-salt
platinum salts, 2 to 4 cycles pre- and postoperatively.
For stomach cancer: Perioperative chemotherapy with Epirubicin and cisplatin-5-FU (ECF),
Epirubicin-oxaliplatin-5FU (EOX) or 5-FU (or LV5FU) - platinum salts, 2 to 4 cycles.
- subscribe to the French national health insurance system and give their written
consent.
- Patient speak and understand French.
- effective contraception for patients of childbearing age
- Patient who for psychiatric social, family or geographical reasons, will not be able
to be monitored and/or compliant with the requirements of the study.
- Patient requiring preoperative radio-chemotherapy. with any unbalanced progressive
disease (hepatic failure, renal failure (creatinine clearance <30mL / min),
respiratory failure, congestive heart failure, myocardial infarction in the last 6
months)
- Patient treated for another cancer within 5 years, except basal cell skin carcinoma
or carcinoma in situ of the cervix.
- patient in legal incapacity (person deprived of liberty or under guardianship).
- cognitive disorders or major disability making it impossible to understand the study
and sign the informed consent
- breastfeeding or pregnancy